NASDAQ : CSTL
Castle Biosciences, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 38.51 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.18B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.14B |
| Enterprise Value | 905.06M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 30.55M |
| Shares Outstanding | 30.55M |
| Shares Change (YoY) | +4.60% |
| Shares Change (QoQ) | +1.71% |
| Owned by Insiders (%) | 1.91% |
| Owned by Institutions (%) | 80.77% |
| Float | 27.19M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.18 |
| Forward PS | 2.90 |
| PB Ratio | 2.41 |
| P/TBV Ratio | 3.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 26.63 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.04 |
| Quick Ratio | 5.60 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.02 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -4.20% |
| Return on Assets (ROA) | -1.36% |
| Return on Invested Capital (ROIC) | -5.04% |
| Return on Capital Employed (ROCE) | -2.38% |
| Weighted Average Cost of Capital (WACC) | 9.18% |
| Revenue Per Employee | $356,565 |
| Profits Per Employee | -$19,376 |
| Employee Count | 1,002 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 8.58 |
Taxes
| Measure | Value |
|---|
| Income Tax | 212,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.95 |
| 52-Week Price Change | +56.53% |
| 50-Day Moving Average | 34.22 |
| 200-Day Moving Average | 28.53 |
| Relative Strength Index (RSI) | 60.87 |
| Average Volume (20 Days) | 348,051 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.02M |
| Short Previous Month | 2.00M |
| Short % of Shares Out | 6.60% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 5.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 357.28M |
| Gross Profit | 276.03M |
| Operating Income | -12.01M |
| Pretax Income | -19.20M |
| Net Income | -19.42M |
| EBITDA | -16.52M |
| EBIT | -12.01M |
| Loss Per Share | -$0.65 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 266.81M |
| Total Debt | 36.65M |
| Net Cash | 230.16M |
| Net Cash Per Share | $7.53 |
| Equity (Book Value) | 470.03M |
| Book Value Per Share | 15.41 |
| Working Capital | 284.59M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 42.63M |
| Capital Expenditures | -43.12M |
| Depreciation & Amortization | -4.51M |
| Net Borrowing | -106,000 |
| Free Cash Flow | -489,000 |
| FCF Per Share | -$0.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | 77.26% |
| Operating Margin | -3.36% |
| Pretax Margin | -5.37% |
| Profit Margin | -5.43% |
| EBITDA Margin | -4.62% |
| EBIT Margin | -3.36% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.60% |
| Shareholder Yield | -4.60% |
| Earnings Yield | -1.76% |
| FCF Yield | -0.04% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $46.70 |
| Price Target Difference | 25.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 11.54% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.77 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |